M. Ahn

发表

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

S-H. Jung, S. Lee, J. Sun, 2022, ESMO open.

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Drilon, R. Doebele, R. Dziadziuszko, 2018, Journal of Thoracic Oncology.

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

R. Swaby, N. Ngamphaiboon, V. Sriuranpong, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

A. Drilon, M. Awad, J. Gray, 2022, Annals of Oncology.

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

J. Machiels, K. Harrington, R. Mehra, 2022, Annals of Oncology.

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

P. Jänne, D. Planchard, M. Aregay, 2022, Annals of Oncology.

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

L. Sequist, S. Novello, F. de Marinis, 2022, Journal of Thoracic Oncology.

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

S. Paik, M. Ahn, B. Cho, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

P. Jänne, L. Sequist, J.-Y. Han, 2021 .

1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)

C. Rudin, C. Hann, L. Paz-Ares, 2022, Annals of Oncology.

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study

Dohoung Kim, Y. Min, S. Shin, 2018, Journal of Thoracic Oncology.

OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

P. Paik, J. Mazières, Y. Wu, 2022, Journal of Thoracic Oncology.

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

E. Cho, E. Felip, A. Delmonte, 2022, Annals of Oncology.

MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI

Jong-Mu Sun, K. Park, J. O. Park, 2019, Journal of Thoracic Oncology.

858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

C. Ho, R. Swaby, N. Ngamphaiboon, 2021, Annals of Oncology.

509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

H. Hayashi, L. Paz-Ares, H. Zebger-Gong, 2023, Annals of Oncology.

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

H. Hayashi, H. Zebger-Gong, M. Ahn, 2023, Annals of Oncology.

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

E. Felip, L. Paz-Ares, H. Zebger-Gong, 2023, Annals of Oncology.